Understand the source comparison
LL-37 and VIP: Direct Mechanism and Application Comparison
The difference between LL-37 and VIP extends beyond nomenclature into entirely distinct biological roles. LL-37 operates through physical membrane disruption and innate immune recruitment; VIP functions through receptor-mediated signal transduction affecting g
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The difference between LL-37 and VIP extends beyond nomenclature into entirely distinct biological roles. LL-37 operates through physical membrane disruption and innate immune recruitment; VIP functions through receptor-mediated signal transduction affecting gene expression and smooth muscle tone. LL-37 is synthesized primarily by neutrophils and epithelial cells at barrier surfaces; VIP is produced by neurons in the peripheral and central nervous systems, as well as immune cells under specific activation states. Their tissue distribution, receptor targets, half-lives, and experimental dosing protocols share no overlap.
- Primary Mechanism
- Direct membrane disruption via amphipathic alpha-helix insertion; pore formation causes osmotic lysis
- VPAC1/VPAC2 receptor binding → cAMP elevation → PKA activation → cytokine modulation and smooth muscle relaxation
- LL-37 is structural/physical; VIP is signaling/biochemical. Not interchangeable
- Amino Acid Length
- 37 amino acids, derived from hCAP18 C-terminal cleavage by proteinase-3
- 28 amino acids, processed from 170-amino-acid prepro-VIP precursor
- Different precursor processing and maturation pathways
- Target Receptors
- FPRL1, P2X7, VEGFR2 (chemotaxis and angiogenesis); no single dedicated receptor for antimicrobial action
- VPAC1 (broad tissue), VPAC2 (smooth muscle, CNS). Both Gs-coupled GPCRs
- VIP has defined receptor pharmacology; LL-37 acts through multiple low-affinity interactions
- Half-Life
- Hours to days depending on tissue environment and protease exposure
- Approximately 2 minutes in circulation due to rapid enzymatic degradation
- VIP requires continuous infusion or frequent dosing; LL-37 persists longer at local sites
- Primary Research Use
- Antimicrobial studies, wound healing, barrier immunity, chronic infection models
- Autoimmune disease, neuroprotection, inflammatory bowel disease, pulmonary hypertension
- Choose LL-37 for pathogen defense; VIP for cytokine suppression and vascular modulation
- Immune Effect
- Recruits neutrophils, monocytes, T-cells; neutralizes endotoxin; promotes tissue repair
- Suppresses TNF-α, IL-6, IL-12; increases IL-10; shifts Th1 to Th2 balance
- LL-37 activates innate immunity; VIP dampens adaptive immunity
- Dosing in Models
- 5–50 μg/mL in vitro; 1–5 mg/kg subcutaneous or topical in vivo
- 10–100 nM in vitro; 25–50 μg/kg intravenous or intraperitoneal in vivo
- Concentration ranges differ by two orders of magnitude. Protocols are not transferable